Conditions: COPD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1071
Healthy volunteers: no

Brief summary:
This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment.

Detailed description:
None provided.

Arms:
arm 1: Active arm 2: Placebo

Interventions: intervention 1: Perforomist-Placebo intervention 2: Perforomist, nebulization, COPD
Intervention descriptions: intervention 1: Placebo vehicle, 2mL, twice daily for 52 weeks intervention 2: Perforomist, 20 mcg/2 mL, twice daily for 52 weeks

Protocol document: